What is PEComa?
PEComa stands for perivascular epithelioid cell tumour. It is a rare tumour of soft tissue and internal organs built from an unusual cell type, the perivascular epithelioid cell (PEC), which tends to gather around the walls of small blood vessels.
PEC cells are puzzling because they carry features of two different cell families at once: they make proteins normally found in pigment cells (melanocytes) and proteins normally found in smooth muscle. No normal counterpart of this cell has ever been clearly identified in healthy tissue.
The name PEComa is used in two ways. In a broad sense it covers a family of related tumours, including angiomyolipoma of the kidney, lymphangioleiomyomatosis (LAM) of the lung and the clear cell “sugar” tumour of the lung. In a narrow sense, and in this article, it refers to PEComa not otherwise specified (NOS), the member of the family that can arise almost anywhere in the body.
Most PEComas are found in adult women, and the uterus and gut are among the commonest sites. Many behave in a benign way, but a proportion are malignant and can spread to the lungs, liver or bones (Izubuchi and Tanaka, 2025).
Some PEComas are linked to tuberous sclerosis complex (TSC), an inherited condition. This link explains why medicines that block the mTOR pathway can shrink advanced tumours.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Mesenchymal (connective tissue) tumour made of perivascular epithelioid cells |
| How common | Very rare; probably fewer than 1 new case per million people each year for PEComa NOS |
| Typical age | Adults, most often 30-60 years; children occasionally |
| Sex | Clearly more common in women |
| Common sites | Uterus, stomach and bowel, retroperitoneum, abdominal wall and pelvis, kidney, liver, bladder, skin |
| Behaviour | From benign to malignant; judged by size and microscopic features |
| Main treatment | Complete surgical removal |
| Advanced disease | mTOR inhibitors such as nab-sirolimus, sirolimus or everolimus |
| Outlook | Excellent for benign-type tumours; serious when malignant and spread |
2. The PEComa family
| Family member | Usual site | Notes |
|---|---|---|
| Angiomyolipoma | Kidney, sometimes liver | Contains fat, muscle-like cells and thick vessels; usually benign; common in TSC |
| Epithelioid angiomyolipoma | Kidney | A variant with more potential to behave aggressively |
| Lymphangioleiomyomatosis (LAM) | Lungs, lymph nodes | Causes cysts in the lungs, almost always in women |
| Clear cell “sugar” tumour | Lung | Small benign nodule, usually found by chance |
| PEComa NOS | Uterus, gut, soft tissue and many organs | The focus of this article |
3. Causes and risk factors
In most people the cause of PEComa is not known. There is no known link with diet, lifestyle, injury or infection.
Gene changes
Researchers have found two main groups of gene changes in PEComa:
| Group | Gene change | What it does | Notes |
|---|---|---|---|
| TSC-related | Loss of TSC2 or, less often, TSC1 | Switches on the mTOR growth pathway | The commonest group; explains response to mTOR inhibitors |
| TFE3-rearranged | TFE3 gene fusion | Overactivates a gene that controls cell metabolism | Often younger patients; nested clear cells; may respond less well to mTOR drugs |
These gene changes are usually found only in the tumour cells. They are not passed on to children (Izubuchi and Tanaka, 2025).
Tuberous sclerosis complex
A minority of people with PEComa NOS have tuberous sclerosis complex, an inherited condition caused by a faulty TSC1 or TSC2 gene. TSC also causes skin patches, seizures, kidney angiomyolipomas and LAM. Doctors may suggest genetic assessment if there are other signs of TSC or more than one tumour.
| Risk factor | Notes |
|---|---|
| Female sex | Women are affected several times more often than men |
| Tuberous sclerosis complex | Raises the risk of several PEComa family tumours |
| Age | Mostly working-age adults |
4. How does it look
To the patient
Many PEComas are deep inside the body and cannot be seen or felt. When they are near the surface, for example in the abdominal wall or limbs, they may feel like a firm, painless lump. Skin PEComas look like a small pink or skin-coloured bump.
During surgery
| Feature | Description |
|---|---|
| Shape | A rounded or lobulated mass, sometimes with a thin capsule |
| Size | From under 2 cm to over 20 cm; malignant tumours are often larger |
| Cut surface | Grey-tan, pale yellow or reddish |
| Bleeding and dead tissue | Common in larger, more aggressive tumours |
| Edges | Pushing in benign tumours; infiltrating nearby tissue in malignant ones |
On scans
On CT and MRI, PEComa usually appears as a well-defined mass with a rich blood supply that lights up strongly after contrast. Bleeding, dead areas and, in angiomyolipoma, fat may also be seen. These findings are suggestive but not specific, so a biopsy or removal is needed for diagnosis.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Epithelioid (rounded) or spindle-shaped cells with clear to pink, grainy cytoplasm |
| Arrangement | Nests and sheets around thin blood vessels |
| Melanocytic markers | HMB-45 and Melan-A positive |
| Muscle markers | Smooth muscle actin and desmin often positive |
| Other stains | Cathepsin K positive; TFE3 strongly positive in TFE3-rearranged tumours |
| Not seen | S100 and SOX10 are usually negative, which helps separate PEComa from melanoma |
5. Symptoms
Symptoms depend mainly on where the tumour grows and how big it is. Small tumours often cause no symptoms and are found by chance on a scan done for another reason.
Common symptoms by site
| Site | Possible symptoms |
|---|---|
| Uterus | Heavy, irregular or post-menopausal bleeding; pelvic pain or pressure |
| Stomach or bowel | Tummy pain, bleeding, anaemia, a change in bowel habit, blockage |
| Retroperitoneum and abdomen | Swelling, fullness, back or tummy pain |
| Kidney | Blood in the urine, flank pain |
| Liver | Discomfort under the right ribs; often no symptoms |
| Bladder | Blood in the urine, needing to pass urine often |
| Skin or soft tissue | A slowly growing lump |
General symptoms
- Tiredness, often from anaemia caused by bleeding
- Weight loss in advanced disease
- Sudden pain if a tumour bleeds internally
Symptoms of spread
| Site of spread | Possible symptoms |
|---|---|
| Lungs | Cough, breathlessness |
| Liver | Tummy pain, jaundice |
| Bone | Bone pain, fracture |
| Peritoneum | Abdominal swelling, fluid in the abdomen |
When to seek medical advice
See a doctor about unusual vaginal bleeding, blood in the urine or stool, a lump that is growing, or tummy pain or swelling that does not settle. These symptoms have many common causes, but they should always be checked.
6. Diagnosis
| Test | Purpose |
|---|---|
| Clinical examination | Checks for a lump and signs of tuberous sclerosis |
| Ultrasound, CT or MRI | Shows the size and position of the tumour and any spread |
| PET-CT | Sometimes used to look for spread |
| Biopsy or surgical removal | Provides tissue for diagnosis |
| Immunohistochemistry | Shows the typical mix of melanocytic and muscle proteins |
| Molecular testing | Looks for TFE3 fusions or TSC1 or TSC2 changes |
| Endoscopy, cystoscopy or hysteroscopy | Examines the gut, bladder or womb lining when those organs are involved |
Is it benign or malignant?
Pathologists use the Folpe criteria to estimate the risk of spread (Folpe et al., 2005). The main warning features are:
| Warning feature | Notes |
|---|---|
| Size over 5 cm | Larger tumours behave worse |
| Infiltrative growth | Tumour cells invade nearby tissue |
| High nuclear grade and cellularity | Very abnormal, crowded cells |
| Mitoses more than 1 per 50 high-power fields | A sign of fast cell division |
| Necrosis | Areas of dead tumour |
| Vascular invasion | Tumour cells inside blood vessels |
| Category | Definition | Usual behaviour |
|---|---|---|
| Benign | No warning features | Very unlikely to come back or spread |
| Uncertain malignant potential | Only large size, or only nuclear atypia with multinucleated giant cells | Low risk, but follow-up advised |
| Malignant | Two or more warning features | Risk of recurrence and spread |
Uterine PEComas are assessed with a modified set of criteria designed for the womb, but the principle is the same.
Conditions that can look similar
PEComa can be mistaken for melanoma, gastrointestinal stromal tumour (GIST), leiomyosarcoma, clear cell sarcoma and renal cell carcinoma. A specialist sarcoma pathologist should review the diagnosis.
7. Treatment
Treatment is planned by a sarcoma multidisciplinary team, including surgeons, oncologists, radiologists and pathologists.
Surgery
Complete removal with clear margins is the main treatment for PEComa that has not spread. The type of operation depends on the site:
| Site | Typical operation |
|---|---|
| Uterus | Hysterectomy, or removal of the tumour alone in selected cases |
| Stomach or bowel | Removal of the affected segment |
| Kidney | Partial or complete nephrectomy |
| Liver | Liver resection |
| Soft tissue | Wide excision |
Treatment for advanced or spread disease
| Option | Notes |
|---|---|
| nab-sirolimus | An albumin-bound form of sirolimus approved in the USA for advanced malignant PEComa; in the AMPECT trial about 4 in 10 people had tumour shrinkage, often lasting years (Wagner et al., 2021; Wagner et al., 2024) |
| Sirolimus, everolimus or temsirolimus | Tablet or infusion mTOR inhibitors used in many countries; responses reported in many small series |
| Chemotherapy | Doxorubicin, gemcitabine or other sarcoma drugs; limited benefit |
| VEGF-targeted drugs | Such as pazopanib, in selected cases |
| Radiotherapy | To control pain or local disease |
| Clinical trials | Recommended where available |
Tumours with TSC2 changes seem more likely to respond to mTOR inhibitors than TFE3-rearranged tumours (Wagner et al., 2021).
Side effects of treatment
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, infection, bleeding, loss of function of the affected organ |
| mTOR inhibitors | Mouth ulcers, tiredness, rash, raised blood sugar and cholesterol, low blood counts, lung inflammation (pneumonitis), more infections |
| Chemotherapy | Nausea, hair loss, low blood counts, tiredness |
| Radiotherapy | Skin soreness, tiredness, effects on nearby organs |
8. Outlook (prognosis)
The outlook for PEComa varies widely and depends mostly on whether the tumour is benign or malignant.
| Situation | Usual outlook |
|---|---|
| Benign-type tumour, completely removed | Excellent; most people are cured |
| Uncertain malignant potential | Generally good, but long-term follow-up is needed |
| Malignant, localised and removed | Recurrence or spread in a substantial proportion |
| Metastatic disease | Serious, but mTOR inhibitors can control the disease for long periods in some people |
Spread most often affects the lungs, liver, bones and peritoneum, and can appear years after surgery (Folpe et al., 2005).
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic review | Check for symptoms and examine the area |
| CT or MRI scans | Every 3-6 months at first for malignant tumours, then less often |
| Chest imaging | To detect lung spread early |
| Long-term review | Advised for many years, as late relapse can occur |
| Blood tests during mTOR treatment | Blood counts, sugar, cholesterol and kidney function |
10. Living with PEComa
- Keep all follow-up appointments, even if you feel well
- Report new symptoms such as bleeding, pain, cough or weight loss
- Use a soft toothbrush and mouthwash if you take an mTOR inhibitor, to reduce mouth ulcers
- Tell all your doctors about mTOR medicines, which can interact with other drugs and vaccines
- Ask about genetic assessment if you or relatives have signs of tuberous sclerosis
- Seek support from sarcoma charities and rare cancer groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is PEComa cancer? | Some PEComas are benign and some are malignant (a type of sarcoma) |
| Is PEComa inherited? | Usually not, but some people have tuberous sclerosis, which is inherited |
| Is it the same as angiomyolipoma? | They are related members of the same family but are classed separately |
| Why is it treated with sirolimus? | Many PEComas have overactive mTOR signalling, which sirolimus blocks |
| Can PEComa come back after surgery? | Benign tumours rarely do; malignant ones can, sometimes years later |
| Can I still have children? | This depends on the site and surgery; ask about fertility options before uterine surgery |
12. Questions to ask your care team
- Is my tumour benign, uncertain or malignant, and why?
- Was it completely removed?
- Has it been tested for TFE3 or TSC2 changes?
- Should I be checked for tuberous sclerosis?
- Would an mTOR inhibitor or a clinical trial suit me?
- How often will I need scans, and for how long?
Resources
- Folpe, A.L. et al. (2005) ‘Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature’, American Journal of Surgical Pathology, 29(12), pp. 1558-1575.
- Izubuchi, Y. and Tanaka, T. (2025) ‘PEComa-its clinical features, histopathology, and current therapy’, Japanese Journal of Clinical Oncology, 55(7), pp. 691-698.
- Wagner, A.J. et al. (2021) ‘nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors’, Journal of Clinical Oncology, 39(33), pp. 3660-3670.
- Wagner, A.J. et al. (2024) ‘Phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): long-term efficacy and safety update’, Journal of Clinical Oncology, 42(13), pp. 1472-1476.
- Henske, E.P. et al. (2016) ‘Tuberous sclerosis complex’, Nature Reviews Disease Primers, 2, 16035.
- Hamza, A. and Guo, C.C. (2020) ‘Perivascular epithelioid cell tumor of the urinary bladder: a systematic review’, International Journal of Surgical Pathology, 28(4), pp. 393-400.
- National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.